Episode Highlights: 0:16 Intro 0:28 Overview of presentation 0:38 Acne and post-inflammatory hyperpigmentation 01:35 Approaches to take 03:21 Rosacea, use of dermoscopy and symptomatology assessment 04:59 Necessity of inclusivity in clinical trials, other knowledge gaps 06:05 Images used in education The American Academy of Dermatology (AAD) Annual…

In the medical community, a revolving cast of players plays a pivotal role in advancing scientific discovery and enhancing patient outcomes. During the research stage, a collaborative team effort, from the clinical trial sponsors to research sites and patient populations, is essential to ensure smooth progress and sustain momentum toward the finish…

A special double-episode of New Insight with Veeral Sheth, MD features a well-rounded conversation on all things ophthalmology with returning guest David Eichenbaum, MD, the director of research for Retina Vitreous Associates of Florida, as well as first-time guest Roger Goldberg, MD, a vitreoretinal surgeon at Bay Area Retina Associates. The trio …

In every episode of New Insight, Veeral Sheth, MD, Director of Clinical Trials at University Retina in Chicago, takes an in-depth look at the biggest news in ophthalmology and the behind the scenes work involved in eye care, with a rotation of guest experts involved in ophthalmic research, development, and clinical care. The latest episode of New I…

On the floor at AAO 2023, host Veeral Sheth, MD, and producer Connor Iapoce discuss UBX1325 for patients with diabetic macular edema, based on the 48-week results from the phase 2 BEHOLD study. Episode Highlights: 0:30 Introduction 0:48 Background into UBX1325 and BEHOLD 2:49 BEHOLD 48-week results 6:05 Next steps 6:56 Conclusion Please direct any …

Episode Highlights 0:12 Intro 1:24 Challenges in autoimmune hepatitis 3:30 Patient demographics 4:25 Diagnostic challenges 6:35 What is overlap syndrome? 8:04 Mysteries behind immune dysregulation 9:05 Promising drugs in investigation 10:51 The BAFF receptor target 11:41 Infliximab & rituximab 12:38 An autoimmune hepatitis wishlist 15:29 Outro Auto…

Host Veeral Sheth, MD is joined by Megan Baldwin, PhD, CEO and Managing Director of Opthea Limited, to discuss OPT-302 or sozinibercept, the company's novel anti-VEGF-C / VEGF-D treatment for wet AMD and other retinal diseases. Episode Highlights: 0:06 Introduction 0:37 Background of Dr. Baldwin 9:56 Promising data on OPT-302/sozinibercept 16:39 Ma…

Warren Jones, PhD, scientific founder of EarliTec Diagnostics and autism expert, discusses his team's development of an eye-tracking device recently authorized by the FDA and proven in clinical trials to predict autism consistent with expert diagnoses.By HCPLive.com

After a historically low-transmission summer, new cases, hospitalizations and deaths due to COVID-19 have increased by approximately 18% in the US over the last week, according to CDC data. In a new DocTalk interview, Donald J. Alcendor, PhD, associate professor, department of pathology microbiology and immunology, division of infectious diseases, …

In this episode, host Veeral Sheth, MD, and producer Connor Iapoce discuss 5 important presentations from ASRS 2023. The discussion centers around new data on geographic atrophy therapies, novel agents for DME, and the feasibility of home OCT. Please direct any podcast-related inquiries to ciapoce@mjhlifesciences.com.…

The newest episode of New Insight with Veeral Sheth, MD features a conversation with David Eichenbaum, MD, the director of research for Retina Vitreous Associates of Florida. A seasoned clinical trial investigator and a friendly face at major medical meetings, Eichenbaum provides insights into his goals behind mentorship and inspiring others, shari…

In the latest episode of New Insight, Veeral Sheth, MD sat down with Cedric Francois, MD, PhD, co-founder and chief executive officer/president of Apellis Pharmaceuticals. The two experts discussed the company's landmark therapy, pegcetacoplan (SYFOVRE™), for geographic atrophy and the decades-long journey toward FDA approval. Sheth also asked abou…

In this episode, Veeral Sheth, MD, sits down with Jay Duker, MD, the president and chief operating officer of Eyepoint Pharmaceuticals, for a discussion on his storied career in ophthalmology, the importance of fostering a relationship between clinicians and industry, and the current biotech Dr. Duker and team are working on at Eyepoint. Please dir…

In this episode, Charles Wykoff, MD, PhD joins Dr. Sheth to provide insight into the recent landmark approval of pegcetacoplan injection (SYFOVRE™) for geographic atrophy, how clinical practice has changed as a result, and both the early struggles with and optimism for an ever-changing treatment landscape. Please direct any podcast-related inquirie…

As part of our ARVO 2023 coverage, Dr. Sheth sat down with Pravin Dugel, MD, President of Iveric Bio. Together, the experts discussed the lead molecule for the company, avacincaptad pegol for geographic atrophy, and touched on the data being presented at the conference, as well as a look back at Dugel's career and his transition into industry.…

The inaugural episode of New Insight with Veeral Sheth, MD, our premier ophthalmology-focused podcast, features a conversation with Arshad Khanai, MD, the Director of Clinical Research at Sierra Eye Associates in Reno, Nevada. Together, our experts discuss their background and education in retina, and how they started working on clinical trials. Th…

The latest offering from HCPLive Podcasts is New InSight with Veeral Sheth, MD, an in-depth series examining the biggest news in ophthalmology. The podcast will feature conversations on research news and new therapies, landmark findings from major medical meetings, and the day-to-day life of an ophthalmologist in the 21st century. A range of guests…

By HCPLive.com

By HCPLive.com

Lawrence Eichenfield, MD, reviews major drug approvals and advancement of screening and prevention strategies for the youngest patients with atopic dermatitis.By HCPLive.com

As 2022 concludes, a dermatologist reflects on the first drug approved for vitiligo.By HCPLive.com

Dr. Lally of New England Retina Consultants joins to discuss avacincaptad pegol, a promising injection treatment for GA, and its supporting data from the GATHER trial program. Will the complement C5 inhibitor drug receive FDA approval in 2023? Lally discusses this and more on the latest DocTalk.By HCPLive.com

Ahead of the American College of Rheumatology 2022 Convergence meeting on Nov. 10-14, our editorial team sat down with planning committee member Zsuzsanna McMahan, MD, MHS, of Johns Hopkins University School of Medicine, to take a deep dive into the upcoming meeting.By HCPLive.com

The FDA is expected to announce the final decision for the dual therapy AT-GAA, which uses miglustat in combination with cipaglucosidase alfa for treating Pompe disease, an inherited and often times fatal disorder. Expert Barry Byrne discusses the characteristics of the condition and what this FDA decision will mean for treatment.…

One of the most notable topics discussed at the 2022 American Academy of Ophthalmology Meeting in Chicago was new advancements in geographic atrophy (GA) treatment. A form of advanced age-related macular degeneration (AMD), there are no currently available treatments for the debilitating disease. In this episode of DocTalk, we spoke with Arshad Kha…

In the wake of Newborn Screening Awareness Month, this episode dives into a novel diagnostic precision medicine guidance tool called BeginNGS. Catherine Nester, RN, and Dr. Stephen Kingsmore, discuss the pivotal role of newborn screening in diagnosing rare diseases. As representatives from collaborating partners Inozyme Pharma and Rady Children's I…

Martha Gulati, MD, Director of Preventive Cardiology, Associate Director of the Barbara Streisand Women’s Heart Center, Associate Director of Preventive and Cardiac Rehabilitation at Cedars-Sinai Medical Center, joins Heart Team to discuss current challenges in women’s cardiovascular disease research and clinical advancement. Gulati also provides g…

By HCPLive.com

In the first episode from this new cardiovascular medicine series, hosts Dr. Jorge Plutzky and Dr. Michael Farkouh speak with University of Maryland's Dr. Matthew Weir about the growing involvement of renal care in modern heart disease patients.By HCPLive.com

The second episode of the 2-part Rare Disease Report shifts to a clinical perspective with the expertise of Dr. Pestana, a pediatric epileptologist at the Epilepsy Center, Cleveland Clinic Neurological Institute who treats patients with CDKL5 deficiency disorder (CDD).By HCPLive.com

In the first episode of a 2-part Rare Disease Report, Whitney Mitchell, mother and caregiver to her 6 year old daughter Havilah, shared her experience leading up to, and now living with, Havilah’s CDKL5 deficiency disorder (CDD) diagnosis.By HCPLive.com

By HCPLive.com

By HCPLive.com

By HCPLive.com

This past week, the American Society of Retina Specialists (ASRS) held its 40th Annual Meeting in New York City to discuss landmark data and the newest advancements in retina care. The HCPLive team was on-site at the Javits Center in Manhattan conducting interviews with expert retina specialists on topics including drugs for neovascular age-related…

On Monday, the US Food and Drug Administration (FDA) approved ruxolitinib cream 1.5% for the treatment of nonsegmental vitiligo in adults and pediatric patients 12 years and older, making it both the first FDA-approved therapy for repigmentation and the only topical formulation of a JAK inhibitor approved in the United States. The groundbreaking ap…

Last week, the US Food and Drug Administration (FDA) approved the co-treatment of pegloticase (Krystexxa) injection plus methotrexate (MTX) for uncontrolled gout, a decision bolstered by data from phase 4 of the MIRROR study. In that study, 71% of patients who were treated with this combination therapy achieved a complete response over the course o…

Despite a bevy of biologics available for people struggling with Crohn’s disease and ulcerative colitis (UC), not all patients are able to respond to or tolerate a vast majority of approved therapies. Fortunately, new data presented at Digestive Disease Week (DDW) 2022 suggests that ustekinumab (STELARA) could function as an alternative option to b…

If you’ve been keeping an eye on recent developments in ophthalmic care, then you’ll know that several new therapeutic agents that had been approved by the US Food and Drug Administration (FDA) in recent months, including ranibizumab delivered via Port Delivery System (PDS) and faricimab, the latter of which became the first-of-its-kind intravitrea…

Earlier this month, dupilumab became the first and only biologic medicine approved by the US Food and Drug Administration for the treatment of atopic dermatitis in patients of all ages, from infancy through adulthood. The approval of dupilumab as an add-on maintenance therapy for children 6 months to 5 years with moderate to severe atopic dermatiti…

On June 13, the US Food and Drug Administration (FDA) approved oral baricitinib (Olumiant) tablets for the treatment of severe alopecia areata in adults, which marked the first approval of a systemic treatment for the disorder. The approval has excited patients and providers alike who struggled for decades to treat severe cases of this autoimmune d…

On June 13, the US Food and Drug Administration (FDA) approved oral baricitinib (Olumiant) tablets for the treatment of severe alopecia areata in adults, which marked the first approval of a systemic treatment for the disorder. The approval has excited patients and providers alike who struggled for decades to treat severe cases of this autoimmune d…

After presenting at the SLEEP 2022 annual meeting, Dr. Aric Prather explains the findings of his previous research demonstrated lack of sleep (6 hours or less) was associated with a 4 times higher risk of becoming sick after exposure to rhinovirus in an interview with HCPLive. Currently, Prather and his team at UCSF are working with a large naive p…

In recognition of National Scleroderma Awareness Month, HCPLive spoke with several prominent dermatologists today who addressed some of the concerns and advancements related to the rare, multi-system disease. Scleroderma is often referred to as “morphea” by dermatologists, and the condition typically presents with the tightening and hardening of th…

By HCPLive.com

Mikkael Sekeres, MD, is no stranger to rare disease. In his own words, there are rare diseases and then there are very rare diseases. Sickle cell is a rare condition with an incidence rate of just over 100 per 100,000 people. Sekeres focuses much of his treatment on patients with bone marrow disorders like myelodysplastic syndromes (MDS) and acute …

Last week, the US Food and Drug Administration approved tapinarof cream, 1% (VTAMA) for the treatment of plaque psoriasis of all severities in adult patients, ushering in the first and only FDA-approved steroid-free topical medication in its class. Remarkably, it had been 25 years since a novel chemical entity had been introduced into psoriasis car…

In recent years, the acknowledgement of cardiac involvement in patients with sarcoidosis has become increasingly important. Thanks to advanced screening techniques, new research has suggested that approximately 2-5% of patients with sarcoidosis also struggle with cardiac sarcoidosis. However, the practice of adding echocardiography and ambulatory E…

Benjamin Nowell, PhD, and Stuart Silverman, MD, FACP, FACR, discuss the recent publication of a new review article, “Cannabis for rheumatic disease pain: A review of current literature.” Investigators discovered that progress in understanding cannabis-based therapies for treating the pain associated with rheumatic disease is hindered due to a lack …

Beyond vaccination, what are some methods for treating COVID-19 in both inpatient and outpatient settings? In the 2 years since the beginning of the pandemic, the strategies for protecting people from this deadly virus have certainly evolved, yet questions remain regarding COVID-19 therapeutics and their availability in certain communities and duri…